SAN DIEGO, and SEOUL, South Korea, Feb. 14 /PRNewswire/ -- ChemDiv, Inc., a leading provider of discovery chemistry services, and SK Corporation, Korea’s leading integrated energy and chemical company, announced that they have extended the previous collaboration through 2008. Under this agreement, ChemDiv is exclusively supplying SK Corporation with discovery chemistry libraries and medicinal chemistry services in addition to assisting the company in hit-to-lead optimization projects initiated at SK Institute of Technology in Daejeon. Financial details were not disclosed.
“We are very proud that SK Corporation, Korea’s leading integrated energy and chemical company and a pioneer in new drug development business, maintains ChemDiv as the partner for their new drug discovery research projects,” said Nikolay Savchuk, President of ChemDiv. “This collaboration is an indicator of continued confidence in the value ChemDiv brings as a partner to the SK Corporation Drug Discovery Program.
“We look forward to our continued collaboration with ChemDiv,” said Dr. Byongsung Kwak, Head of BioPharmaceutical Division of SK Corporation. “We are confident that the company’s diverse sets of drug-like small molecules and their state-of-the-art facilities and capabilities in both the US and Europe will continue to be a significant asset to SK Corporation in our research, development, manufacturing and marketing of drugs, active substances and intermediates.”
About ChemDiv, Inc.
ChemDiv, Inc. (ChemDiv) is a global chemistry-driven contract research organization focused on the delivery of new scientific innovation, products and services that meet the drug discovery needs of its partners. ChemDiv provides partners with access to Discovery outSource(TM), a full service drug discovery capabilities encompassing: medicinal chemistry; pre-clinical development; synthetic chemistry; diverse and focused screening libraries, as well as global logistics. For additional information, please visit http://www.chemdiv.com.
About SK Corporation
SK Corporation is a research and development division specializing in the discovery of small molecule drug candidates and their development. SK Corporation’s research programs focus on designing compounds to treat neurological, psychiatric, pain, inflammations and metabolic diseases and asthma. For additional information, please visit http://www.skrnd.com/eng/ and http://skbp.com.
ChemDiv, Inc.; SK Corporation
CONTACT: Viacheslav Katin, Business Development of ChemDiv, Inc.,+1-858-794-4860, or fax, +1-858-794-4931, vk@chemdiv.com; or Sang Rak ChoiSenior Scientist of SK Corporation, 82-42-866-7442, or fax, 82-42-866-7702,srchoi@skcorp.com
